Ubs Group Ag Marker Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
SELL
$0.24 - $4.58 $10,281 - $196,207
-42,840 Reduced 91.95%
3,753 $1,000
Q3 2022

Nov 10, 2022
BUY
$0.3 - $3.73 $12,904 - $160,445
43,015 Added 1202.21%
46,593 $17,000
Q2 2022

Aug 10, 2022
SELL
$0.26 - $0.46 $606 - $1,073
-2,333 Reduced 39.47%
3,578 $1,000
Q1 2022

May 16, 2022
SELL
$0.37 - $1.0 $1,790 - $4,839
-4,839 Reduced 45.01%
5,911 $3,000
Q4 2021

Feb 14, 2022
BUY
$0.95 - $1.72 $10,212 - $18,490
10,750 New
10,750 $10,000
Q3 2021

Nov 15, 2021
SELL
$1.68 - $2.88 $14,673 - $25,153
-8,734 Closed
0 $0
Q2 2021

Aug 13, 2021
SELL
$1.88 - $3.56 $15,923 - $30,153
-8,470 Reduced 49.23%
8,734 $25,000
Q1 2021

May 12, 2021
BUY
$1.47 - $3.29 $12,960 - $29,007
8,817 Added 105.13%
17,204 $39,000
Q4 2020

Feb 11, 2021
BUY
$1.36 - $1.75 $5,298 - $6,818
3,896 Added 86.75%
8,387 $12,000
Q3 2020

Nov 12, 2020
SELL
$1.5 - $2.2 $9,756 - $14,308
-6,504 Reduced 59.15%
4,491 $7,000
Q2 2020

Jul 31, 2020
SELL
$1.69 - $2.79 $8,086 - $13,350
-4,785 Reduced 30.32%
10,995 $23,000
Q1 2020

May 01, 2020
SELL
$1.59 - $3.35 $39,365 - $82,939
-24,758 Reduced 61.07%
15,780 $30,000
Q4 2019

Feb 14, 2020
BUY
$2.68 - $4.85 $46,085 - $83,400
17,196 Added 73.67%
40,538 $117,000
Q3 2019

Nov 14, 2019
SELL
$4.1 - $9.0 $11,828 - $25,965
-2,885 Reduced 11.0%
23,342 $119,000
Q2 2019

Aug 14, 2019
BUY
$5.15 - $7.92 $43,157 - $66,369
8,380 Added 46.95%
26,227 $208,000
Q1 2019

May 14, 2019
BUY
$5.1 - $6.71 $86,694 - $114,063
16,999 Added 2004.6%
17,847 $118,000
Q4 2018

Feb 14, 2019
BUY
$4.2 - $9.74 $3,561 - $8,259
848 New
848 $5,000

Others Institutions Holding MRKR

# of Institutions
5
Shares Held
475K
Call Options Held
0
Put Options Held
0
View Full List

About Marker Therapeutics, Inc.

MRKR Quotes by TradingView
  • Ticker MRKR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,599,200
  • Market Cap $259M
  • Description
  • Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...
More about MRKR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email